US equities |
MU $986.43 ▼-4.14% META $743.38 ▲+3.44% NVDA $226.39 ▼-1.26% SNDK $1,478.61 ▼-6.52% SPCX $164.03 ▲+0.90% AMD $589.71 ▼-3.02% MSFT $540.18 ▲+0.96% TSLA $378.33 ▼-1.14%
FinancialContent

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

3.270 -0.050 (-1.51%)
Delayed Quote Updated: 1:29 PM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
News headline image
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
Oral GLP-1 market projected to expand from $5.1 billion in 2026 to $89 billion in 2034 Novo announces additional weight-loss in patients switching from injected to oral delivery 
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Updates Financial Position
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Announces Closing of Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds
Kelowna, British Columbia – September 9, 2026 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today closed its... 
Via TheNewswire.com
News headline image
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Receives USD$2.6 Million Tax Rebate Payment
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Receives USD$2.6 Million Tax Rebate Payment
Lexaria’s 2025 Australian human study results in a USD$2.6 million cash rebate 
Via TheNewswire.com
News headline image
DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Enters a Material Transfer Agreement With PegBio
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Announces Effective Date for Reverse Stock Split
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria Updates Business Development
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
From Lexaria Bioscience Corp.
Via ACCESS Newswire
News headline image
Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
Via ACCESS Newswire
News headline image
Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
Via ACCESS Newswire
News headline image
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
Via ACCESS Newswire
News headline image
Lexaria Bioscience Releases Second Episode of Investor Video Series
Via ACCESS Newswire
News headline image
Lexaria Updates Progress on Human Study #7
Via ACCESS Newswire
News headline image
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
Via ACCESS Newswire
News headline image
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
Via ACCESS Newswire
News headline image
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
Via ACCESS Newswire
News headline image
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
Via ACCESS Newswire
News headline image
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
Via ACCESS Newswire
News headline image
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
Via ACCESS Newswire
News headline image
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
The number of oral weight-loss / diabetes drug treatments is expanding, increasing demand for the reduction of side effects 
Via TheNewswire.com
News headline image
Lexaria to Begin New Human Clinical Study in GLP-1
Via ACCESS Newswire
News headline image
Lexaria's Robust Patent Portfolio Continues to Grow
Via ACCESS Newswire
News headline image
Lexaria's Oral GLP-1 Drug Strategy Validated by Industry
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >